This Checkpoint Inhibitors market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $32.41 billion in 2024 to $37.88 billion in 2025 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to rising incidence of cancer, increasing awareness of checkpoint inhibitors, expanding range of approved checkpoint inhibitors, research and development on checkpoints novel inhibitors, clinical trials and research.
The checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $55.64 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to expanding indications, biomarker discovery, combination therapies, personalized medicine, and expanded indications. Major trends in the forecast period include precision immunotherapy, immune checkpoint combinations, cell therapy integration, biosimilars, and immunotherapy combinations.
The increasing prevalence of cancer cases worldwide is expected to drive the growth of the checkpoint inhibitors market in the coming years. Cancer is a collection of diseases characterized by the uncontrolled proliferation and dissemination of abnormal cells, which can invade surrounding tissues and spread to other areas of the body. The rise in cancer cases is attributed to factors such as aging populations, unhealthy lifestyles (including smoking and poor diet), environmental exposures (such as pollution and radiation), genetic factors, and infections like HPV and hepatitis. Checkpoint inhibitors work by blocking proteins that inhibit immune cells, allowing the immune system to more effectively recognize and attack cancer cells. For example, in September 2024, the American Cancer Society, a professional organization based in the U.S., projected that by 2050, the number of global cancer cases in men will increase by 84%, rising from 10.3 million in 2022 to 19 million, while cancer-related deaths are expected to grow by 93%, from 5.4 million in 2022 to 10.5 million. Consequently, the rising incidence of cancer worldwide is anticipated to significantly enhance the demand for checkpoint inhibitors.
The rising healthcare expenditure is anticipated to drive the growth of the checkpoint inhibitors market in the future. Healthcare expenditure refers to the total financial resources allocated to healthcare goods and services over a specific period, usually within a particular country or region. This expenditure related to checkpoint inhibitors includes a broad spectrum of activities, ranging from drug development and manufacturing to patient access and support services. It is vital for ensuring the availability of these innovative cancer treatments while maintaining their safety and efficacy. For example, in October 2024, a report from the Centers for Medicare and Medicaid Services, a U.S. government agency, indicated that in 2022, hospital expenditures rose by 2.2% to reach $1.35 trillion, while expenditures for physician and clinical services increased by 2.7% to $884.9 billion, both reflecting a more moderate growth rate compared to 2021. Additionally, national health expenditure (NHE) is projected to have grown by 7.5% in 2023, exceeding the GDP growth rate of 6.1%. Therefore, the upward trend in healthcare expenditure is expected to significantly contribute to the growth of the checkpoint inhibitors market.
Leading companies in the checkpoint inhibitor market are actively developing advanced technologies, including oral checkpoint inhibitors. Many cancer patients do not respond effectively to traditional immune checkpoint inhibitors, which is where oral checkpoint inhibitors come in. These innovative cancer immunotherapy drugs are designed to be taken orally and work by blocking immune checkpoints such as PD-1/PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells. For example, in September 2024, OmRx Oncology, a biopharmaceutical company based in the U.S., launched OX-4224, an oral checkpoint inhibitor that targets the PD-1/PD-L1 pathway specifically for non-small cell lung cancer (NSCLC). This investigational drug aims to offer a more affordable alternative to existing biologic checkpoint inhibitors, thereby increasing access to cancer immunotherapy worldwide. A Phase 2 study is planned in India to evaluate its safety and efficacy in patients with advanced NSCLC. Additionally, OmRx intends to expand its use in low- and middle-income countries, focusing on enhancing cancer care globally.
Keytruda (pembrolizumab), an immunotherapy drug categorized as a checkpoint inhibitor, exemplifies the innovation in the checkpoint inhibitors market. Merck & Co., Inc. obtained FDA approval in March 2022 for Keytruda to treat patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial carcinoma. Keytruda's mechanism involves enabling the immune system to identify and combat cancer cells by blocking checkpoint proteins, offering an effective treatment avenue either individually or in combination with other cancer therapies.
In July 2024, Boehringer Ingelheim, a pharmaceutical company based in Germany, acquired Nerio Therapeutics for a sum of up to $1.3 billion. This acquisition allows Boehringer to access Nerio's preclinical research on checkpoint inhibitors, which focuses on inhibiting the enzymes PTPN1 and PTPN2 to boost the immune system's response to tumors. Nerio Therapeutics is a biotechnology startup located in the U.S. that specializes in developing immuno-oncology drugs and preclinical immune checkpoint inhibitors.
Checkpoint inhibitors represent a form of immunotherapy that disrupts the interaction between immune checkpoint proteins, enabling T cells to combat cancer cells by avoiding the suppression signal. Among these medications, one targets the checkpoint protein CTLA-4.
Within the realm of checkpoint inhibitors, the primary drug categories include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, chimeric antigen receptor T-cells (CAR-T), and other variants. PD-1 and PD-L1 inhibitors specifically hinder the function of immune checkpoint proteins present on cell surfaces, aiding in the treatment of conditions like lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, and more. These therapies find application across diverse sectors encompassing hospital pharmacies, retail pharmacies, and online pharmacy services.
The checkpoint inhibitors market research report is one of a series of new reports that provides checkpoint inhibitors market statistics, including checkpoint inhibitors industry global market size, regional shares, competitors with a checkpoint inhibitors market share, detailed checkpoint inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitors industry. This checkpoint inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the checkpoint inhibitors market include AstraZeneca plc, Bristol-Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Innate Pharma S.A., Ono Pharmaceutical Co. Ltd., Eli Lilly and Company, Sanofi S.A, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim International GmbH, Celgene Corporation, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Kyowa Kirin Co. Ltd., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Zai Lab Limited.
North America was the largest region in the checkpoint inhibitors market in 2024. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The checkpoint inhibitors market consists of sales of atezolizumab, avelumab, and durvalumab. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $32.41 billion in 2024 to $37.88 billion in 2025 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to rising incidence of cancer, increasing awareness of checkpoint inhibitors, expanding range of approved checkpoint inhibitors, research and development on checkpoints novel inhibitors, clinical trials and research.
The checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $55.64 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to expanding indications, biomarker discovery, combination therapies, personalized medicine, and expanded indications. Major trends in the forecast period include precision immunotherapy, immune checkpoint combinations, cell therapy integration, biosimilars, and immunotherapy combinations.
The increasing prevalence of cancer cases worldwide is expected to drive the growth of the checkpoint inhibitors market in the coming years. Cancer is a collection of diseases characterized by the uncontrolled proliferation and dissemination of abnormal cells, which can invade surrounding tissues and spread to other areas of the body. The rise in cancer cases is attributed to factors such as aging populations, unhealthy lifestyles (including smoking and poor diet), environmental exposures (such as pollution and radiation), genetic factors, and infections like HPV and hepatitis. Checkpoint inhibitors work by blocking proteins that inhibit immune cells, allowing the immune system to more effectively recognize and attack cancer cells. For example, in September 2024, the American Cancer Society, a professional organization based in the U.S., projected that by 2050, the number of global cancer cases in men will increase by 84%, rising from 10.3 million in 2022 to 19 million, while cancer-related deaths are expected to grow by 93%, from 5.4 million in 2022 to 10.5 million. Consequently, the rising incidence of cancer worldwide is anticipated to significantly enhance the demand for checkpoint inhibitors.
The rising healthcare expenditure is anticipated to drive the growth of the checkpoint inhibitors market in the future. Healthcare expenditure refers to the total financial resources allocated to healthcare goods and services over a specific period, usually within a particular country or region. This expenditure related to checkpoint inhibitors includes a broad spectrum of activities, ranging from drug development and manufacturing to patient access and support services. It is vital for ensuring the availability of these innovative cancer treatments while maintaining their safety and efficacy. For example, in October 2024, a report from the Centers for Medicare and Medicaid Services, a U.S. government agency, indicated that in 2022, hospital expenditures rose by 2.2% to reach $1.35 trillion, while expenditures for physician and clinical services increased by 2.7% to $884.9 billion, both reflecting a more moderate growth rate compared to 2021. Additionally, national health expenditure (NHE) is projected to have grown by 7.5% in 2023, exceeding the GDP growth rate of 6.1%. Therefore, the upward trend in healthcare expenditure is expected to significantly contribute to the growth of the checkpoint inhibitors market.
Leading companies in the checkpoint inhibitor market are actively developing advanced technologies, including oral checkpoint inhibitors. Many cancer patients do not respond effectively to traditional immune checkpoint inhibitors, which is where oral checkpoint inhibitors come in. These innovative cancer immunotherapy drugs are designed to be taken orally and work by blocking immune checkpoints such as PD-1/PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells. For example, in September 2024, OmRx Oncology, a biopharmaceutical company based in the U.S., launched OX-4224, an oral checkpoint inhibitor that targets the PD-1/PD-L1 pathway specifically for non-small cell lung cancer (NSCLC). This investigational drug aims to offer a more affordable alternative to existing biologic checkpoint inhibitors, thereby increasing access to cancer immunotherapy worldwide. A Phase 2 study is planned in India to evaluate its safety and efficacy in patients with advanced NSCLC. Additionally, OmRx intends to expand its use in low- and middle-income countries, focusing on enhancing cancer care globally.
Keytruda (pembrolizumab), an immunotherapy drug categorized as a checkpoint inhibitor, exemplifies the innovation in the checkpoint inhibitors market. Merck & Co., Inc. obtained FDA approval in March 2022 for Keytruda to treat patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial carcinoma. Keytruda's mechanism involves enabling the immune system to identify and combat cancer cells by blocking checkpoint proteins, offering an effective treatment avenue either individually or in combination with other cancer therapies.
In July 2024, Boehringer Ingelheim, a pharmaceutical company based in Germany, acquired Nerio Therapeutics for a sum of up to $1.3 billion. This acquisition allows Boehringer to access Nerio's preclinical research on checkpoint inhibitors, which focuses on inhibiting the enzymes PTPN1 and PTPN2 to boost the immune system's response to tumors. Nerio Therapeutics is a biotechnology startup located in the U.S. that specializes in developing immuno-oncology drugs and preclinical immune checkpoint inhibitors.
Checkpoint inhibitors represent a form of immunotherapy that disrupts the interaction between immune checkpoint proteins, enabling T cells to combat cancer cells by avoiding the suppression signal. Among these medications, one targets the checkpoint protein CTLA-4.
Within the realm of checkpoint inhibitors, the primary drug categories include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, chimeric antigen receptor T-cells (CAR-T), and other variants. PD-1 and PD-L1 inhibitors specifically hinder the function of immune checkpoint proteins present on cell surfaces, aiding in the treatment of conditions like lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, and more. These therapies find application across diverse sectors encompassing hospital pharmacies, retail pharmacies, and online pharmacy services.
The checkpoint inhibitors market research report is one of a series of new reports that provides checkpoint inhibitors market statistics, including checkpoint inhibitors industry global market size, regional shares, competitors with a checkpoint inhibitors market share, detailed checkpoint inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitors industry. This checkpoint inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the checkpoint inhibitors market include AstraZeneca plc, Bristol-Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Innate Pharma S.A., Ono Pharmaceutical Co. Ltd., Eli Lilly and Company, Sanofi S.A, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim International GmbH, Celgene Corporation, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Kyowa Kirin Co. Ltd., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Zai Lab Limited.
North America was the largest region in the checkpoint inhibitors market in 2024. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The checkpoint inhibitors market consists of sales of atezolizumab, avelumab, and durvalumab. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Checkpoint Inhibitors Market Characteristics3. Checkpoint Inhibitors Market Trends and Strategies4. Checkpoint Inhibitors Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Checkpoint Inhibitors Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Checkpoint Inhibitors Market34. Recent Developments in the Checkpoint Inhibitors Market
5. Global Checkpoint Inhibitors Growth Analysis and Strategic Analysis Framework
6. Checkpoint Inhibitors Market Segmentation
7. Checkpoint Inhibitors Market Regional and Country Analysis
8. Asia-Pacific Checkpoint Inhibitors Market
9. China Checkpoint Inhibitors Market
10. India Checkpoint Inhibitors Market
11. Japan Checkpoint Inhibitors Market
12. Australia Checkpoint Inhibitors Market
13. Indonesia Checkpoint Inhibitors Market
14. South Korea Checkpoint Inhibitors Market
15. Western Europe Checkpoint Inhibitors Market
16. UK Checkpoint Inhibitors Market
17. Germany Checkpoint Inhibitors Market
18. France Checkpoint Inhibitors Market
19. Italy Checkpoint Inhibitors Market
20. Spain Checkpoint Inhibitors Market
21. Eastern Europe Checkpoint Inhibitors Market
22. Russia Checkpoint Inhibitors Market
23. North America Checkpoint Inhibitors Market
24. USA Checkpoint Inhibitors Market
25. Canada Checkpoint Inhibitors Market
26. South America Checkpoint Inhibitors Market
27. Brazil Checkpoint Inhibitors Market
28. Middle East Checkpoint Inhibitors Market
29. Africa Checkpoint Inhibitors Market
30. Checkpoint Inhibitors Market Competitive Landscape and Company Profiles
31. Checkpoint Inhibitors Market Other Major and Innovative Companies
35. Checkpoint Inhibitors Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Checkpoint Inhibitors Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on checkpoint inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for checkpoint inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The checkpoint inhibitors market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4; Chimeric Antigen Receptor T-cell; Other Drugs2) By Application: Lung Cancer; Renal Cancer; Blood Cancer; Bladder Cancer; Melanoma; Other Applications
3) By End-Users: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By PD-1 Inhibitors: Pembrolizumab (Keytruda); Nivolumab (Opdivo)2) By PD-L1 Inhibitors: Atezolizumab (Tecentriq); Durvalumab (Imfinzi); Avelumab (Bavencio)
3) By CTLA-4: Ipilimumab (Yervoy)
4) By Chimeric Antigen Receptor T-cell: CAR T-cell Therapy Products
5) By Other Drugs: Combination Therapies; Emerging Checkpoint Inhibitors
Key Companies Mentioned: AstraZeneca plc; Bristol-Myers Squibb Company; Merck & Co. Inc.; Roche Holding AG; Pfizer Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Checkpoint Inhibitors market report include:- AstraZeneca plc
- Bristol-Myers Squibb Company
- Merck & Co. Inc.
- Roche Holding AG
- Pfizer Inc.
- Incyte Corporation
- Novartis AG
- GlaxoSmithKline plc
- Innate Pharma S.A.
- Ono Pharmaceutical Co. Ltd.
- Eli Lilly and Company
- Sanofi S.A
- AbbVie Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Gilead Sciences Inc.
- Kyowa Kirin Co. Ltd.
- Johnson & Johnson
- Regeneron Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Zai Lab Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 37.88 Billion |
| Forecasted Market Value ( USD | $ 55.64 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
